CORONARY PREVENTION

A Clinical Guide

RICHARD G. HUTCHINSON

CORONARY PREVENTION: A CLINICAL GUIDE

RICHARD G. HUTCHINSON, M.D., F.C.C.P., F.A.C.P., F.A.C.C.

Associate Professor of Medicine
Director, Preventive Cardiology Teaching Program
Attending Physician
University Hospital
The University of Mississippi School of Medicine
Jackson, Mississippi



YEAR BOOK MEDICAL PUBLISHERS, INC.
CHICAGO

Copyright © 1985 by Year Book Medical Publishers, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher. Printed in the United States of America.

0 9 8 7 6 5 4 3 2 1

Library of Congress Cataloging in Publication Data

Hutchinson, Richard G. Coronary prevention.

Includes bibliographies and index.

1. Coronary heart disease—Prevention. I. Title.

[DNLM: 1. Coronary Disease—Prevention & control.

WG 300 H977c]

RC685.C6H88 1985 616.1'2305 85-5292

ISBN 0-8151-4790-2

Sponsoring Editor: James D. Ryan, Jr. Editing Supervisor: Frances M. Perveiler

Copyeditor: Francis A. Byrne

Production Project Manager: R. Allen Reedtz Proofroom Supervisor: Shirley E. Taylor

CORONARY PREVENTION: A CLINICAL GUIDE

To the families of the authors with affection and appreciation.

Contributors

W. STEWART AGRAS, M.D., F.R.C.P.(C)

Professor of Psychiatry and Behavioral Science Stanford University School of Medicine Stanford, California

FREDERICK W. ARENSMAN, M.D., F.A.A.P.

Assistant Professor of Pediatrics Medical College of Georgia Attending Physician Eugene Talmadge Memorial Hospital Augusta, Georgia

IAN C. BALFOUR, M.B.B.S., F.A.A.P., F.A.C.C.

Assistant Professor of Pediatrics/Adolescent Medicine St. Louis University School of Medicine Pediatric Cardiologist Cardinal Glennon Children's Hospital St. Louis, Missouri

RICHARD G. HUTCHINSON, M.D.

Associate Professor of Medicine Director, Preventive Cardiology Teaching Program The University of Mississippi School of Medicine Jackson, Mississippi

HERBERT G. LANGFORD, M.D., F.A.C.P.

Professor of Medicine University of Mississippi School of Medicine Chief, Endocrinology and Hypertension Division University of Mississippi Medical Center Jackson, Mississippi

RUSSELL V. LUEPKER, M.D., M.S. (EPIDEMIOLOGY), F.A.C.C.

Associate Professor of Epidemiology and Medicine Division of Epidemiology School of Public Health University of Minnesota Attending Physician University of Minnesota Hospitals Minneapolis, Minnesota

MARY A. SOUTHAM, PH.D.

Research Associate
Department of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

WILLIAM B. STRONG, M.D., F.A.A.P., F.A.C.C.

L.H. Charbonnier Professor of Pediatrics
Chief, Section of Pediatric Cardiology
Director, Georgia Institute for the Prevention of Human Disease
and Accidents
Medical College of Georgia
Augusta, Georgia

LAURENCE O. WATKINS, M.D., F.R.C.P.(C), F.A.C.C.

Assistant Professor of Medicine Section of Cardiology Medical College of Georgia Attending Physician Eugene Talmadge Memorial Hospital Augusta, Georgia

NANETTE K. WENGER, M.D., F.A.C.C.

Professor of Medicine Department of Cardiology Emory University School of Medicine Atlanta, Georgia

Foreword

THIRTY-FIVE YEARS AGO coronary heart disease was the leading cause of death in the United States. It was thought to be the inevitable consequence of aging and its prevention was not even considered. A book such as this one would have been unthinkable. Ancel Keys was just beginning his epidemiologic studies relating diet to serum cholesterol and coronary heart disease. The Framingham study was getting cranked up. Effective antihypertensive therapy was still in the investigational stage and attention was just being focused on cigarette smoking as a possible etiologic factor in pulmonary disease, but its relationship to coronary heart disease was not recognized.

In the ensuing three decades the risk factors for atherosclerotic heart disease have been identified, largely from insurance actuarial data and prospective epidemiologic studies such as Framingham, Tecumseh, Albany, and others. Cigarette smoking, hypercholesterolemia, and hypertension have emerged as the three major treatable risk factors, roughly in that order of importance.

But documentation that correction of these risk factors would reduce atherosclerotic heart disease morbidity and mortality has been slow in coming and in achieving acceptance by the community of practicing physicians.

It is generally acknowledged that treatment of hypertension will reduce the risk of stroke because all prospective, controlled treatment trials have demonstrated this. However, only the Hypertension Detection and Follow-up Program (HDFP) has shown a reduction in mortality from atherosclerotic heart disease and these data have been criticized because of the lack of a control group receiving placebo. The Multiple Risk Factor Intervention Trial (MRFIT) has raised searching questions about the possible adverse effects of oral diuretics in management of hypertension in high risk men with abnormal resting electrocardiograms, but this is largely by inference as there are no hard data to support this.

There is general agreement that within a few months after cessation of cigarette smoking the risk of myocardial infarction and/or sudden death is reduced.

The Lipid Research Clinics' primary prevention trial demonstrated a reduction in coronary events, fatal and nonfatal, this was roughly proportional to the reduction in serum cholesterol concentration, although overall mortality rate was not affected.

Secondary prevention has also been evaluated. A Mayo Clinic study showed that effective antihypertensive treatment reduced overall mortality and myocar-

X Foreword

dial infarction for patients who had angina and/or a previous myocardial infarction. Several well controlled trials have documented the value of beta blockers in preventing sudden death and recurrent myocardial infarction for up to 30 months after an acute myocardial infarction.

There is less evidence that correcting other risk factors (obesity, sedentary life style, diabetes) will reduce the risk of atherosclerotic heart disease unless the corrective measures also affect the primary risk factors.

The bottom line is that mortality from atherosclerotic heart disease has declined by more than 25 percent in the last 10 years in the United States. How much of this can be attributed to risk reduction and how much to better medical care of those already affected with the disease is speculative, but primary prevention has to be playing a role. In the United Kingdom where management of risk factors is less aggressive than it has been in this country, the coronary death rate has not declined.

Nevertheless, atherosclerotic heart disease is still the leading cause of death in the United States. However, it is now apparent that it is not the inevitable result of aging. It is preventable and this book by Dr. Richard Hutchinson and colleagues speaks to this issue.

RAY W. GIFFORD, JR., M.D. CHAIRMAN, DEPARTMENT OF HYPERTENSION AND NEPHROLOGY THE CLEVELAND CLINIC FOUNDATION CLEVELAND, OHIO

Preface

For Several Decades the medical profession has been absorbed with the development and application of dramatic and effective methods of managing life-threatening cardiovascular crises. The importance of this is undeniable. Unfortunately, however, we have been slow in setting our sights on preventing these crises from occurring in the first place. Clearly, to emphasize treatment over prevention leaves logic behind. When possible, should we not prevent fires from starting rather than putting them out after they have begun? Public health professionals and the lay public have been significantly ahead of us in instigating life-style and other changes which have played a major role in the sharp decline in coronary heart disease mortality which has occurred in the last several decades. However, in recent years there has been increasing interest by physicians in the less dramatic, but all important, concept of prevention.

Ironically, because progress has been made in reducing coronary heart disease mortality and morbidity, there is a danger that complacency may set in, despite the fact that coronary heart disease is still the leading cause of death in the United States.

Given the foregoing considerations, this book has been written to stimulate physicians to wage the battle of prevention, to provide them with a clear discussion of the pathophysiologic actions of the various risk factors, and to provide detailed recommendations for intervention against the latter. Furthermore, the text is broad in scope and embraces all three facets of prevention,* primary, secondary, and tertiary.

Since primary care physicians and cardiologists have the greatest opportunities to have a major impact in the various facets of prevention, this book will be particularly useful to these groups, but it will be equally useful to practitioners in other fields who are concerned with reducing coronary heart disease morbidity and mortality.

RICHARD G. HUTCHINSON, M.D.

xii Preface

*Three Facets of Prevention:

Primary: Keeping the disease (e.g., coronary heart disease) from occur-

ring.

Secondary: Treating the disease once it has occurred, to prevent complica-

tions and recurrences.

Tertiary: Attempting to minimize (prevent) the consequences once the dis-

ease and its complications have supervened (e.g, cardiac rehabil-

itation).

Acknowledgments

The author-editor would like to express a special word of appreciation to Ms. Jane Johnson for the truly outstanding secretarial and administrative assistance she provided.

Special appreciation is also accorded Dr. Bonnie Noe for the superb job she did in the realm of essential library research.

Recognition is also extended to the following for their significant secretarial assistance to the chapter authors:

Ms. Jean Newman
Mrs. Judy Cassady
Ms. Carolyn Davis
Ms. Carolyn Brakefield
Ms. Jean M. Larson
Ms. Julia Wright
and
Ms. Jeanette Zahler.

Last, but not least, appreciation is expressed to the staff at Year Book Medical Publishers: Sponsoring Editor, James Ryan, Jr.; Editing Supervisor, Fran Perveiler; Copyeditor, Francis Byrne; Production Project Manager, R. Allen Reedtz; and Proofroom Supervisor, Shirley Taylor, for their patience, skill, and good work.

Contents

Preface	. 1 4
Sudden Death	. 1 . 3 . 4
Sudden Death	. 1 . 3 . 4
	. 4
	. 4
	. 4
Risk Factors	. 4
Modification of Risk Factors	
2 / Pediatric Aspects of Atherosclerosis and Hypertension: The Physician's Responsibility by Frederick W. Arensman, William B. Strong, Laurence O. Watkins, Ian C. Balfour	. 9
Definitions	. 11
Pathology, Natural History, Clinical Course of Atherosclerosis	. 11
Risk Factors	. 13
Intervention	. 35
Recommendations	. 36
Conclusions	. 39
3 / Hypertension and Coronary Artery Disease by Herbert G. Langford	. 47
Hypertension as a Risk Factor	. 47
Hypertension, Atherosclerosis, and Myocardial Infarction	. 47
Effects of Myocardial Hypertrophy	. 48
Vasodilator Reserve	. 48
Coronary Occlusion and Hypertension	. 48
Myocardial Infarction and Blood Pressure	. 49
Antihypertensive Therapy and Coronary Artery Disease	. 50
Coronary Heart Disease During Randomized Trials of Hypertension Treatment	. 51
Cause-Specific Mortality in HDFP	
Antihypertensive Therapy and Coronary Heart Disease in the HDFP	
Antihypertensive Therapy and Nonspecific ST-T Abnormalities of the EKG	
Recent Myocardial Infarction and Hypertension	

xvi Contents

Preventive Therapy	55
Antihypertensive Therapy in Coronary Heart Disease	56
4 / Cigarettes: Why They Are Harmful and How to Get People	
to Stop Smoking by Richard G. Hutchinson	
Prevalence of Smoking	
Why People Smoke	
Involuntary Smoking	62
Why Smoking is Bad	
Noncardiovascular Effects	68
Preventing the Habit	
Getting the Patient to Quit	
Other Quit Smoking Approaches	
Appendix: Smoking Cessation	83
5 / Diet and Coronary Heart Disease: The Role of Lipids and Obesity	-
by Russell V. Leupker	
Diet, Lipids, and Coronary Heart Disease	
Patient Evaluation	
Treatment of Hyperlipidemia	
Obesity	
Diagnosis and Treatment	117
6 / Everysian and Commons Heart Disease h. Disk and C. H. d.	100
6 / Exercise and Coronary Heart Disease by Richard G. Hutchinson Evidence of a Beneficial Effect	
Selection as a Factor	
Exercise and Longevity Post-myocardial Infarction	
Evidence for Exercise Inefficacy	
Secondary Benefits of Exercise	
Direct Benefits	
Physiologic Considerations	
Risks	
Preexercise Screening	
Prodromal Symptoms	
Constituents of a Good Exercise Program	
Conclusions	142
7 / Studen and Studen Management in C	
7 / Stress and Stress Management in Coronary Heart Disease by Mary A. Southam, W. Stewart Agras	145
Stress and Coronary Heart Disease	
The Management of Stress in Coronary Heart Disease Prevention	

CONTENTS xvi	ii
8 / Other Risk Factors by Richard G. Hutchinson	1
The Role of Estrogen in Coronary Heart Disease	
Diabetes Mellitus as a Risk Factor	
Family History	
9 / Risk Modifiers by Richard G. Hutchinson	39
Platelet Active Drugs	19
Clinical Trials	
The Beta Blocking Drugs	
Coronary Artery Bypass Surgery	13
10 / Coronary Rehabilitation as Prevention by Nanette K. Wenger)7
Background Information)8
Limitation of the Adverse Physiologic and Emotional Consequences of the Acute Illness)9
Identification of Patients at Increased Risk of Early Reinfarction	
or Sudden Cardiac Death and the Institution of Therapy to Lessen	
This Risk	22
Amelioration of Symptoms by a Variety of Medical and Surgical	20
Therapies With Consequent Improvement in Function	29
Measures to Retard the Progression or Induce Regression of the Atherosclerotic Disease	30
Maintenance and Enhancement of Residual Functional Status	
Summary: Current Status and Unmet Needs	
Summary. Carrone status and Omnet recons	. 1
Appendix: Exercise Prescriptions	55

1 / Magnitude of the Problem

RICHARD G. HUTCHINSON, M.D.

CARDIOVASCULAR DISEASES account for almost one million deaths annually in the United States, more than all other diseases combined (Table 1–1). Over 200,000 of these occur before the age of 65, mostly from coronary heart disease (CHD). Over 50% of all cardiovascular deaths are due to coronary heart disease, and total over one-half million per year. In men over age 40 and women over 50–55, CHD is the leading cause of death.^{1, 2} Coronary heart disease deaths outnumber those from cancer by more than one-third.

As distressing as these figures are, they do not take into account the numerous nonfatal cardiac events and the attendant emotional stress for both the victims and their families, the medical expenses, time lost from work and, often, temporary or permanent disability. In fact, over 16 million people in the United States have partial or complete disability from cardiovascular disease with the probability that about one half of these are attributable to coronary heart disease.

Coronary disease becomes a problem for men much earlier than for women. While the degree of difference between male and female susceptibility diminishes with age, men remain at greater risk at all ages. White males between 35–44 have five times the coronary heart disease mortality of women of the same age group and maintain this ratio until the 55–64 age bracket when it falls to a figure still in excess of 3:1 (Table 1–2). This sex difference can also be expressed as a time lag which is about a decade in length. For example, the coronary mortality risk for white females at age 45–54 is approximately that of their male counterparts at age 35–44. This pattern for white females persists all the way through the 65–74 age bracket. For nonwhites too, there is a considerable difference in male-female mortality over the decades, but the difference does not approximate that between white men and women.

While the etiology for the male-female gap remains unclear, it may be mediated at least in part by sex hormone differences. Hormonal factors are discussed in more detail in the chapter entitled Other Risk Factors.

SUDDEN DEATH

Of the three modes by which coronary heart disease manifests itself, sudden death, myocardial infarction, and angina pectoris, sudden death poses the most

TABLE	1-1DE	EATHS IN	1978	AND	1979	FOR
SELECTE	D CAUSES	OF DEA	тн: U	NITED	STA	TES*

	NUMBER OF DEATHS		
CAUSE OF DEATH	1978†	1979†	
All causes	1,924,000	1,895,380	
Cardiovascular Diseases	985,785	967,953‡	
Coronary heart disease	641,140	545,200	
Stroke	172,520	167,320	
Hypertensive disease	15,480	30,330	
Rheumatic heart disease	12,790	7,420	
Congenital heart disease	6,445	6,445‡	
All other CV disease	137,410	211,240	
All Other Causes	938,215	927,425	
Cancer	396,060	401,450	
Accidents, poisonings, violence	159,970	153,850	
Influenza and pneumonia	58,290	43,770	
Cirrhosis of the liver	29,910	29,620	
Diabetes	32,780	32,780	
COPD including asthma	46,810	49,580	
All other causes	214,395	216,375	

^{*}Source: Vital Statistics from the National Center for Health Statistics. Reprinted by permission of the National Heart, Lung, and Blood Institute.

difficult problem. There is even confusion regarding its definition. However, one major study of previous myocardial infarction victims, the Aspirin Myocardial Infarction Study (AMIS),³ defined it as death within one hour of the onset of symptoms. Lown⁴ defined it as death occurring within an hour of the initiation of symptoms, or, in the case of unwitnessed death, with the victim

TABLE 1–2.—Age-Specific Mortality Rates per 100,000 Population for Coronary Heart Disease (ICD 410–413): Selected Age Groups by Sex-Color, United States, 1978*

AGE	WHITE MEN	WHITE WOMEN	NONWHITE MEN	NONWHITE WOMEN
35–44	55.9	10.4	87.2	32.2
45-54	254.9	54.7	304.7	139.0
55-64	697.3	211.4	772.1	400.4
65-74	1597.0	692.3	1399.8	895.7
75-84	3736.3	2380.3	2918.6	2334.9
85 +	7597.7	6276.0	3788.5	3297.9

^{*}From Arteriosclerosis: Report of the Working Group on Arteriosclerosis of the National Heart, Lung, and Blood Institute (NHLBI). U.S. Department of HHS, Public Health Service, National Institutes of Health, NIH Publication No. 82–2035, Vol. 2, 1981. Reprinted by permission of NHLBI.

[†]Provisional, based on a 10% sample of death certificates. ‡Estimated by NHLBI.